Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia

Published:2020-01-13 Issue:2 Volume:189 Page:369-378
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Zhang Lunqing¹,Zhang Mingjie¹,Du Xin²,Cheng Yunfeng³,Cheng Gregory¹⁴⁵^ORCID

Affiliation:

1. Faculty of Health Science University of Macau Taipa Macau China

2. Shenzhen Second People’s Hospital Shenzhen China

3. Zhongshan Hospital Fudan University Shanghai China

4. Macau University of Science and Technology Hospital Taipa Macau China

5. Health and Humanity Research Centre Hongkong China

Funder

Novartis Pharmaceuticals (HK) Ltd

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16327

Reference38 articles.

1. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients

2. Response of Resistant Idiopathic Thrombocytopenic Purpura to Pulsed High-Dose Dexamethasone Therapy

3. High Dose Dexamethasone Vs. Conventional Dose Prednisolone for Adults with Immune Thrombocytopenia: a Prospective Multicenter Phase III Trial.

4. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

5. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment;Blood Reviews;2024-09

2. The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives;Frontiers in Immunology;2024-06-24

3. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial;Blood Advances;2024-03-18

4. Progress in the Treatment of Eltrombopag for Adult Primary Immune Thrombocytopenia;Advances in Clinical Medicine;2024

5. Immunomodulation with romiplostim as a second‐line strategy in primary immune thrombocytopenia: The iROM study;British Journal of Haematology;2023-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3